HB Fuller (NYSE:FUL)‘s stock had its “buy” rating reissued by equities researchers at G.Research in a note issued to investors on Tuesday, Zacks.com reports.
FUL has been the subject of a number of other research reports. JPMorgan Chase & Co. decreased their price target on shares of HB Fuller from $51.00 to $46.00 and set a “neutral” rating for the company in a research report on Friday, June 28th. Deutsche Bank set a $50.00 price target on shares of HB Fuller and gave the stock a “hold” rating in a research report on Friday, September 27th. Citigroup downgraded shares of HB Fuller from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $48.00 to $41.00 in a research report on Friday, September 27th. ValuEngine raised shares of HB Fuller from a “sell” rating to a “hold” rating in a research report on Friday, June 28th. Finally, Zacks Investment Research downgraded shares of HB Fuller from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 1st. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $51.80.
Shares of NYSE:FUL opened at $45.53 on Tuesday. The company has a quick ratio of 1.55, a current ratio of 2.36 and a debt-to-equity ratio of 1.77. HB Fuller has a 52-week low of $39.22 and a 52-week high of $51.97. The company has a 50 day moving average of $44.95 and a two-hundred day moving average of $45.97. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of 15.18, a price-to-earnings-growth ratio of 1.49 and a beta of 1.57.
HB Fuller (NYSE:FUL) last released its quarterly earnings results on Wednesday, September 25th. The specialty chemicals company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.04). HB Fuller had a return on equity of 13.20% and a net margin of 4.78%. The company had revenue of $725.38 million for the quarter, compared to analyst estimates of $749.18 million. During the same period in the previous year, the business posted $0.86 EPS. The firm’s quarterly revenue was down 5.8% compared to the same quarter last year. On average, equities analysts anticipate that HB Fuller will post 3 earnings per share for the current year.
In related news, VP Timothy J. Keenan sold 7,500 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $48.82, for a total transaction of $366,150.00. Following the transaction, the vice president now directly owns 27,742 shares in the company, valued at $1,354,364.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James Owens sold 33,275 shares of the firm’s stock in a transaction on Friday, October 4th. The stock was sold at an average price of $46.34, for a total value of $1,541,963.50. Following the transaction, the chief executive officer now owns 219,673 shares in the company, valued at $10,179,646.82. The disclosure for this sale can be found here. Insiders have sold 44,422 shares of company stock worth $2,077,590 over the last 90 days. 3.46% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Arizona State Retirement System lifted its stake in HB Fuller by 0.6% during the second quarter. Arizona State Retirement System now owns 78,935 shares of the specialty chemicals company’s stock worth $3,663,000 after purchasing an additional 483 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in HB Fuller by 5.6% during the second quarter. JPMorgan Chase & Co. now owns 51,018 shares of the specialty chemicals company’s stock worth $2,344,000 after purchasing an additional 2,701 shares during the last quarter. NumerixS Investment Technologies Inc bought a new position in HB Fuller during the first quarter worth $166,000. Atria Investments LLC bought a new position in HB Fuller during the second quarter worth $1,759,000. Finally, Comerica Bank lifted its stake in HB Fuller by 2.1% during the second quarter. Comerica Bank now owns 141,136 shares of the specialty chemicals company’s stock worth $6,731,000 after purchasing an additional 2,912 shares during the last quarter. Hedge funds and other institutional investors own 97.37% of the company’s stock.
About HB Fuller
H.B. Fuller Company, together with its subsidiaries, formulates, manufactures, and markets adhesives, sealants, coatings, polymers, tapes, encapsulants, and other specialty chemical products worldwide. The company operates through five segments: Americas Adhesives, EIMEA, Asia Pacific, Construction Adhesives, and Engineering Adhesives.
Read More: Return on Investment (ROI)
Receive News & Ratings for HB Fuller Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HB Fuller and related companies with MarketBeat.com's FREE daily email newsletter.